Black Hawk Acquisition Corp 8-K

What Happened Black Hawk Acquisition Corp (the Company) filed an 8‑K (Item 5.02) reporting that on January 27, 2026 Michael Bowen, Chief Financial Officer of Vesicor Therapeutics, Inc. (the Company’s proposed business combination target), passed away. On the same day the Vesicor board appointed Mitchell Creem as Vesicor’s Chief Financial Officer, effective immediately. Separately, on January 26, 2026 the Vesicor board appointed Frederick Woodruff Field to its board; the board determined Mr. Field meets Nasdaq “independent director” requirements.

Key Details

• Date of events: Michael Bowen’s death and Creem appointment reported January 27, 2026; Field appointment effective January 26, 2026.
• New CFO: Mitchell Creem — currently CEO and director of Pioneer Acquisition Corporation (Nasdaq: PACH), with 35+ years in healthcare finance and executive roles; no employment agreement between Vesicor and Mr. Creem.
• New director: Frederick Woodruff Field — founder/CEO of Radar Pictures, co‑founder of Interscope Records, with 30+ years in media/entrepreneurship; determined by Vesicor to be Nasdaq‑independent.
• Governance/transactions: No arrangements or understandings led to their selections; no family relationships with Company officers/directors; neither has a direct or indirect material interest in transactions required to be disclosed under Item 404(a) of Regulation S‑K.

Why It Matters For investors, these are material governance and personnel changes at Vesicor, Black Hawk’s proposed merger target. A CFO change — especially due to an unexpected death — can affect Vesicor’s near‑term financial reporting, audit interactions and the merger diligence process. The appointment of an independent board member may affect corporate governance and Nasdaq‑related compliance. Shareholders should watch for further 8‑K updates or proxy/transaction disclosures for any impact on the proposed business combination or its timeline.